Dissecting Response and Resistance to Anti-PD-1 Therapy in Microsatellite-Unstable Gastric Cancer

Area of Science:

• Oncology
• Immunotherapy
• Genomics

Background:

• Microsatellite-unstable (MSI) gastric cancer is a distinct subtype.
• Response rates to anti-PD-1 therapy in MSI gastric cancer vary, with some patients not benefiting.
• The underlying mechanisms for differential response remain unclear.

Purpose of the Study:

• To investigate the role of tumor mutation burden (TMB) in predicting anti-PD-1 therapy response in MSI gastric cancer.
• To explore the impact of immune checkpoint inhibitors (ICIs) on TMB and tumor immunoediting.

Main Methods:

• Analysis of TMB in MSI gastric cancer patients.
• Correlation of TMB levels with response to anti-PD-1 therapy.
• Assessment of changes in TMB following ICI treatment.

Main Results:

• Differences in TMB were identified as a potential driver for variable patient outcomes with anti-PD-1 therapy.
• Treatment with ICIs resulted in further immunoediting in responding patients.
• A reduction in TMB was observed in patients who responded to ICI treatment.

Conclusions:

• TMB is a significant factor influencing the efficacy of anti-PD-1 therapy in MSI gastric cancer.
• ICI treatment induces immunoediting, leading to a decrease in TMB in responders.
• These findings highlight the complex interplay between tumor genetics and immunotherapy response.